Rexahn Pharmaceuticals Awarded Patent in Japan for Novel Targeted Cancer Drug Delivery Platform

ROCKVILLE, Md., July 14, 2015 (GLOBE NEWSWIRE) -- Rexahn Pharmaceuticals, Inc. (NYSE MKT:RNN), a clinical stage biopharmaceutical company developing best-in-class therapeutics for the treatment of cancer, today announced that it was issued patent number 5749273 from the Japanese Patent Office entitled "Polymeric Systems for the Delivery of Anticancer Drugs" for the Company’s novel CPMA drug delivery platform. This new CPMA drug delivery platform technology, developed by Rexahn, enables more precise, targeted delivery of anti-cancer drugs directly into cancer cells.

“There is a significant unmet need in the oncology field for drugs which selectively target and kill cancer cells while sparing normal, healthy cells. By utilizing our proprietary CPMA polymer drug delivery technology and combining it with currently approved anti-cancer drugs, we hope to transport anti-cancer drugs directly into cancerous cells where their cytotoxic activity can be most effective, thereby increasing efficacy and minimizing the harmful side effects associated with traditional cancer therapy,” said Dr. Peter D. Suzdak, Chief Executive Officer. “Rexahn Pharmaceuticals is pleased to be at the forefront of the development of novel, targeted approaches to cancer treatment, which could yield meaningful improvements in quality of life for cancer patients.”

Dr. Suzdak continued, “Rexahn remains committed to ensuring the strongest possible intellectual property protection for our proprietary anti-cancer programs and platform technologies. We are pleased to be issued this latest patent, which expands our intellectual property estate and extends intellectual property protection for the CPMA platform.”

About Rexahn's Proprietary CPMA Drug Delivery Platform

CPMA is a polymer based drug delivery platform for the targeted delivery of anti-cancer compounds directly to cancer cells. The highly versatile chemical properties of CPMA allow it to be covalently linked to a diverse range of anti-cancer compounds together with a signaling moiety directing it to cancer cells and bypassing healthy tissues. Once inside a cancer cell, the covalent linker is metabolized yielding the free anti-cancer compound. CPMA has the flexibility to covalently bind multiple anti-cancer compounds into a single formulation. Because it is highly water soluble, CPMA also enables compounds that are water insoluble to be more effectively delivered and bioavailable.

About Rexahn Pharmaceuticals, Inc.

Rexahn Pharmaceuticals is a clinical stage biopharmaceutical company dedicated to developing best-in-class therapeutics for the treatment of cancer. Rexahn currently has three clinical stage oncology candidates, Archexin®, RX-3117, and SupinoxinTM (RX-5902) and a robust pipeline of preclinical compounds to treat multiple types of cancer. Rexahn has also developed proprietary drug discovery platform technologies in the areas of Nano-Polymer-Drug Conjugate Systems (NPDCS), CPMA, 3D-GOLD (computational predictive modeling), and TIMES (small molecule signaling discovery). For more information, please visit

Safe Harbor

To the extent any statements made in this press release deal with information that is not historical, these are forward-looking statements under the Private Securities Litigation Reform Act of 1995. Such statements include, but are not limited to, statements about Rexahn's plans, objectives, expectations and intentions with respect to future operations and products and other statements identified by words such as "will," "potential," "could," "can," "believe," "intends," "continue," "plans," "expects," "anticipates," "estimates," "may," other words of similar meaning or the use of future dates. Forward-looking statements by their nature address matters that are, to different degrees, uncertain. Uncertainties and risks may cause Rexahn's actual results to be materially different than those expressed in or implied by Rexahn's forward-looking statements. For Rexahn, particular uncertainties and risks include, among others, the difficulty of developing pharmaceutical products, obtaining regulatory and other approvals and achieving market acceptance; the marketing success of Rexahn's licensees or sublicensees; the success of clinical testing; and Rexahn's need for and ability to obtain additional financing. More detailed information on these and additional factors that could affect Rexahn's actual results are described in Rexahn's filings with the Securities and Exchange Commission, including its most recent annual report on Form 10-K and subsequent quarterly reports on Form 10-Q. All forward-looking statements in this news release speak only as of the date of this news release. Rexahn undertakes no obligation to update or revise any forward-looking statement, whether as a result of new information, future events or otherwise.

Contact: Stacey Jurchison Rexahn Investor Relations 240-268-5300 x 324

Source:Rexahn Pharmaceuticals